Xentria is developing the investigational drug XTMAB16 to target tumor necrosis factor (TNF) in patients with pulmonary sarcoidosis, a rare inflammatory disease. The company focuses on building partnerships to guide the clinical development of therapeutics that meet significant unmet medical needs.
Funding
$25M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Pulmonary sarcoidosis, a rare inflammatory disease, lacks targeted and effective treatments, leaving patients with significant unmet medical needs. Current therapies often have limited efficacy or significant side effects. The disease's complex pathophysiology, involving tumor necrosis factor (TNF), requires innovative therapeutic approaches.
Solution
Xentria is developing XTMAB16, an investigational drug specifically targeting tumor necrosis factor (TNF) for patients with pulmonary sarcoidosis. XTMAB16 aims to suppress the physiological response of TNF, addressing the underlying inflammatory processes in this rare disease. The company focuses on building strategic partnerships to guide the clinical development of XTMAB16, leveraging expertise and resources to navigate the complexities of drug development. Xentria's approach seeks to deliver adaptive solutions to ambitious drug innovation, ultimately improving patient outcomes in pulmonary sarcoidosis.
Target Audience
The primary target audience includes patients diagnosed with pulmonary sarcoidosis and the healthcare providers (pulmonologists, rheumatologists) who manage their care.
Features
- Targets tumor necrosis factor (TNF), a key mediator of inflammation in pulmonary sarcoidosis.
- Investigational New Drug (IND) candidate.
- Focus on clinical development through strategic life-sciences partnerships.